AXGN vs SYK
AXGN: Axogen is a medical technology company dedicated to advancing the field of peripheral nerve repair through its portfolio of nerve allografts, conduits, and wrap technologies. SYK: A diversified global MedTech leader providing surgical instruments, robotics, and advanced clinical technologies to enhance patient recovery and healthcare outcomes.
Side-by-side fundamentals
| Metric | AXGN | SYK | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $42.21 | $325.70 | |
| Market cap as of 2026-08-03 | $2.3B | $124.9B | |
| P/E as of 2026-08-03 | n/a | 37.73 | |
| PEG as of 2026-08-03 | -0.11 | 3.68 | AXGN lower |
| Net margin as of 2026-08-03 | -13.2% | +13.2% | SYK higher |
| Gross margin as of 2026-08-03 | +75.0% | +64.2% | AXGN higher |
| Operating margin as of 2026-08-03 | -10.9% | +19.7% | SYK higher |
| ROE as of 2026-08-03 | -20.7% | +15.1% | SYK higher |
| ROA as of 2026-08-03 | -13.5% | +7.1% | SYK higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.64 | AXGN lower |
| Revenue growth (YoY) as of 2026-08-03 | +22.4% | +8.8% | AXGN higher |
| Revenue CAGR (3y) SEC XBRL | +17.6% | +10.8% | AXGN higher |
| Dividend yield as of 2026-08-03 | n/a | +1.1% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-03 | 0.84 | 0.56 | |
| 1-year return as of 2026-07-31 close | +222.5% | -17.1% | AXGN higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.